C57BL/6N-Tnfrsf1atm2a(EUCOMM)Wtsi/H

Status

Available to order

EMMA IDEM:09866
Citation informationRRID:IMSR_EM:09866 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameC57BL/6N-Tnfrsf1atm2a(EUCOMM)Wtsi/H
Alternative nameEPD0971_5_E01
Strain typeTargeted Mutant Strains
Allele/Transgene symbolTnfrsf1atm2a(EUCOMM)Wtsi
Gene/Transgene symbolTnfrsf1a
DisclaimerPlease note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA:
  1. We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted.
  2. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure.
  3. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA.
  4. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider MRC, Medical Research Council
Provider affiliationMary Lyon Centre at MRC Harwell
Genetic informationThis mouse line originates from EUCOMM ES clone EPD0971_5_E01. For further details on the construction of this clone see the page at the IMPC portal.
Phenotypic informationPotential phenotyping data in the IMPC portal
ReferencesNone available

Information from EMMA

Archiving centreMary Lyon Centre at MRC Harwell, Oxford, United Kingdom

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

    • Tumor necrosis factor receptor 1 associated periodic syndrome / Orphanet_32960
IMPC phenotypes (gene matching)
  • abnormal skin morphology / IMPC
  • increased large unstained cell number / IMPC
  • increased grip strength / IMPC
  • increased basophil cell number / IMPC
  • increased neutrophil cell number / IMPC
  • increased eosinophil cell number / IMPC
  • increased NK cell number / IMPC
  • abnormal cholesterol homeostasis / IMPC
  • decreased circulating calcium level / IMPC
  • increased lymphocyte cell number / IMPC
  • increased effector memory CD8-positive, alpha-beta T cell number / IMPC
  • increased circulating aspartate transaminase level / IMPC
  • enlarged heart / IMPC
  • increased leukocyte cell number / IMPC
  • decreased monocyte cell number / IMPC
  • abnormal heart morphology / IMPC
  • decreased neutrophil cell number / IMPC
MGI phenotypes (gene matching)
  • increased bone mineral density / MGI
  • abnormal Peyer's patch morphology / MGI
  • abnormal sleep pattern / MGI
  • abnormal immune system physiology / MGI
  • decreased IgG level / MGI
  • liver inflammation / MGI
  • lung inflammation / MGI
  • decreased inflammatory response / MGI
  • increased skin papilloma incidence / MGI
  • decreased tumor incidence / MGI
  • abnormal respiratory mechanics / MGI
  • abnormal airway responsiveness / MGI
  • abnormal lymph node B cell domain morphology / MGI
  • abnormal spleen germinal center morphology / MGI
  • abnormal Peyer's patch follicle morphology / MGI
  • decreased susceptibility to bacterial infection / MGI
  • increased susceptibility to bacterial infection / MGI
  • abnormal macrophage physiology / MGI
  • granulomatous inflammation / MGI
  • impaired skin barrier function / MGI
  • abnormal glutamate-mediated receptor currents / MGI
  • decreased circulating alanine transaminase level / MGI
  • abnormal cytokine secretion / MGI
  • no phenotypic analysis / MGI
  • abnormal nervous system physiology / MGI
  • abnormal response/metabolism to endogenous compounds / MGI
  • increased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to experimental autoimmune encephalomyelitis / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • increased susceptibility to parasitic infection / MGI
  • increased susceptibility to type I hypersensitivity reaction / MGI
  • decreased Peyer's patch number / MGI
  • abnormal follicular dendritic cell morphology / MGI
  • absent follicular dendritic cells / MGI
  • decreased IgG1 level / MGI
  • increased circulating tumor necrosis factor level / MGI
  • decreased circulating interleukin-6 level / MGI
  • decreased circulating interleukin-1 beta level / MGI
  • increased interleukin-6 secretion / MGI
  • decreased interleukin-6 secretion / MGI
  • abnormal chemokine secretion / MGI
  • decreased susceptibility to endotoxin shock / MGI
  • increased susceptibility to endotoxin shock / MGI
  • decreased physiological sensitivity to xenobiotic / MGI
  • increased sensitivity to induced cell death / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • decreased sensitivity to induced morbidity/mortality / MGI
  • decreased sensitivity to xenobiotic induced morbidity/mortality / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • abnormal neuron proliferation / MGI
  • abnormal oval cell physiology / MGI
  • tumor regression / MGI
  • impaired adaptive thermogenesis / MGI
  • decreased susceptibility to dopaminergic neuron neurotoxicity / MGI
  • decreased microglial cell number / MGI
  • impaired humoral immune response / MGI
  • impaired central nervous system regeneration / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).